ROIVANT SCIENCES LTD (ROIV) Stock News

USA - Nasdaq - NASDAQ:ROIV - BMG762791017 - Common Stock

20.97 USD

-0.21 (-0.99%)

Last: 12/5/2025, 8:00:01 PM

20.97 USD

0 (0%)

After Hours: 12/5/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ROIV Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: The Motley Fool - Mentions: PFE

Roivant (ROIV) Q2 2026 Earnings Call Transcript

17 days ago - By: Benzinga - Mentions: ARWR HSIC HUM LLY ...

10 Health Care Stocks With Whale Alerts In Today's Session

25 days ago - By: Benzinga

Looking Into Roivant Sciences Ltd's Recent Short Interest

26 days ago - By: Zacks Investment Research - Mentions: BFRI

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates

26 days ago - By: Roivant Sciences

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

26 days ago - By: Roivant Sciences

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

a month ago - By: Zacks Investment Research - Mentions: LENZ

LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates

a month ago - By: Roivant Sciences

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

a month ago - By: Roivant Sciences

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

3 months ago - By: Stocktwits - Mentions: VFMO PKW GM

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17

3 months ago - By: The Motley Fool

Why Roivant Sciences Stock Is Soaring Today

3 months ago - By: Investor's Business Daily - Mentions: AAPL

Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease

3 months ago - By: Roivant Sciences

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

3 months ago - By: Roivant Sciences

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

3 months ago - By: Roivant Sciences

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

3 months ago - By: Roivant Sciences

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

3 months ago - By: Pulmovant, Inc.

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

3 months ago - By: Roivant Sciences

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

3 months ago - By: Roivant Sciences

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

3 months ago - By: Yahoo Finance - Mentions: IMVT

Roivant Sciences (ROIV) Announces Q1 2025 Business Update

4 months ago - By: Yahoo Finance

Why Roivant Sciences Stock Bounced Back on Tuesday

4 months ago - By: Yahoo Finance

Why Roivant Sciences Stock Was Slipping on Monday

4 months ago - By: Yahoo Finance - Mentions: ABX UBS TSLA EA ...

Stock Market Today: S&P 500 upgraded by Citi, UBS

4 months ago - By: Zacks Investment Research - Mentions: FENC

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: Roivant Sciences

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

4 months ago - By: Roivant Sciences

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update